Literature DB >> 1806235

Transient ischaemia induced by rapid cardiac pacing results in myocardial preconditioning.

A Vegh1, L Szekeres, J R Parratt.   

Abstract

STUDY
OBJECTIVE: The aim was to determine whether rapid ventricular pacing can protect against the ventricular arrhythmias occurring during a subsequent coronary artery occlusion.
DESIGN: The effect was examined of two 2 min periods of pacing (300 beats.min-1) in chloralose-urethane anaesthetised dogs on a subsequent 25 min coronary artery occlusion. Ventricular arrhythmias, ST segment elevation, and inhomogeneity of conduction were analysed. EXPERIMENTAL MATERIAL: 25 anaesthetised mongrel dogs in a restricted body weight range were used.
MEASUREMENTS AND MAIN RESULTS: Preocclusion pacing reduced the severity of occlusion induced ST segment elevation, degree of inhomogeneity, and arrhythmias: ventricular premature beats were reduced from 528(SEM 40) to 136(45), and there were lower incidences of ventricular fibrillation (0% v 47%) and ventricular tachycardia (30% v 80%).
CONCLUSIONS: Rapid ventricular pacing "preconditions" the myocardium in a manner similar to that following short coronary artery occlusions. Short periods of ischaemia no matter how induced protect the heart against the arrhythmogenic effect of a prolonged coronary artery occlusion.

Entities:  

Mesh:

Year:  1991        PMID: 1806235     DOI: 10.1093/cvr/25.12.1051

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  15 in total

1.  Pacing-induced delayed protection against arrhythmias is attenuated by aminoguanidine, an inhibitor of nitric oxide synthase.

Authors:  A Kis; A Végh; J Papp; J Parratt
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Decisions, directions, defects and fellow disciples (A rückblick of 50 years of basic medical research).

Authors:  James Roy Parratt
Journal:  Exp Clin Cardiol       Date:  2010

3.  The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.

Authors:  M A Rastegar; F Marchini; G Morazzoni; A Vegh; J G Papp; J R Parratt
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  The effect of uraemia on the duration of arrhythmias in the context of cardioprotective ischaemic conditioning strategies.

Authors:  Kieran McCafferty; Conor J Byrne; Julius Kieswich; Martin Raftery; Christoph Thiemermann; Muhammad M Yaqoob
Journal:  Heart Asia       Date:  2014-05-24

5.  Protective role of normothermic, hyperthermic and estrogen preconditioning and pretreatment on tumour necrosis factor-alpha-induced damage.

Authors:  Jasbir S Juggi; Lamia J Hoteit; Fawzi A Babiker; Shaji Joseph; Abu Salim Mustafa
Journal:  Exp Clin Cardiol       Date:  2011

6.  The antiarrhythmic effects of ischaemic preconditioning in anaesthetized dogs are prevented by atropine; role of changes in baroreceptor reflex sensitivity.

Authors:  László Babai; Julius Gy Papp; James R Parratt; Agnes Végh
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  Activation of beta-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction.

Authors:  Peter E Penson; William R Ford; Emma J Kidd; Kenneth J Broadley
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-29       Impact factor: 3.000

Review 8.  Non-ischemic myocardial preconditioning.

Authors:  R Domenech; P Macho
Journal:  Mol Cell Biochem       Date:  1998-09       Impact factor: 3.396

9.  Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway.

Authors:  A Vegh; L Szekeres; J Parratt
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

10.  A common mechanism in the protective effects of preconditioning, cardiac pacing and physical exercise against ischemia and reperfusion-induced arrhythmias.

Authors:  Agnes Végh; James R Parratt
Journal:  Exp Clin Cardiol       Date:  2005
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.